PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?
How the treatment of ALL is changing
The importance of blinatumomab and inotuzumab ozogamicin in treating ALL
Highlights from EHA 2016 press briefings: POLLUX and EURO-SKI trials and BiTE antibodies
Why daratumumab is effective in multiple myeloma - results from the CASTOR trial